HAVCR2 and subcutaneous panniculitis-like T-cell lymphoma: Therefore, based on current evidence, IST-based regimens should be a preferred first-line treatment for patients with SPTCL in all age groups, especially in the presence of HAVCR2 mutations, although specific guidelines for SPTCL have not been established [20].